| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4356 | 2018 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3561 | 2014 |
| Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer VJ Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, ... New England Journal of medicine 350 (4), 351-60, 2004 | 2995* | 2004 |
| First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2489 | 2017 |
| First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2480 | 2017 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1637 | 2015 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1011 | 2019 |
| Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The lancet 387 (10026), 1415-26, 2016 | 932 | 2016 |
| Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial G Zalcman, J Mazieres, jacques Margery, L Greillier, C Audigier-Valette, ... Lancet 387 (10026), 1405-14, 2016 | 921 | 2016 |
| Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. DMB Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA ... New England Journal of Medicine 376 (4), 305-317., 2017 | 837* | 2017 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 790 | 2021 |
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer L Derosa, MD Hellmann, M Spaziano, D Halpenny, M Fidelle, H Rizvi, ... Annals of Oncology 29 (6), 1437-1444, 2018 | 749 | 2018 |
| Pulmonary arterial hypertension in patients treated by dasatinib D Montani, E Bergot, S Günther, L Savale, A Bergeron, A Bourdin, ... Circulation 125 (17), 2128-2137, 2012 | 747 | 2012 |
| Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA oncology 4 (3), 351-357, 2018 | 697 | 2018 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 683 | 2018 |
| Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial E Quoix, G Zalcman, JP Oster, V Westeel, E Pichon, A Lavolé, J Dauba, ... The Lancet 378 (9796), 1079-1088, 2011 | 670 | 2011 |
| Lung cancer in never smokers–a review S Couraud, G Zalcman, B Milleron, F Morin, PJ Souquet European journal of cancer 48 (9), 1299-1311, 2012 | 613 | 2012 |
| Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous … F Barlesi, A Scherpereel, A Rittmeyer, A Pazzola, N Ferrer Tur, JH Kim, ... Journal of Clinical Oncology 31 (24), 3004-3011, 2013 | 539* | 2013 |
| Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer Y Kieffer, HR Hocine, G Gentric, F Pelon, C Bernard, B Bourachot, ... Cancer discovery 10 (9), 1330-1351, 2020 | 466 | 2020 |
| Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 414 | 2015 |
Gérald SIMONNEAUParis Sud university and Marie Lannelongue hospital
